放疗|《柳叶刀·肿瘤学》:对PD-1/PD-L1抑制剂耐药的非小细胞肺癌患者或需另谋出路( 三 )


7.Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, et al. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2022;23(2):279-291. doi:10.1016/S1470-2045(21)00658-6
9.Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373-377. doi:10.1038/nature14292
10.Klug F, Prakash H, Huber PE, et al. Low-dose irradiation programs macrophage differentiation to an iNOS?/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24(5):589-602. doi:10.1016/j.ccr.2013.09.014